SCHEMBL13166235

SCHEMBL13166235

CCOC(=O)c1ccc(OCCNC(=O)OC(C)(C)C)c(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.46
MAPT P10636 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
IDO1 P14902 3/20 0.45
AAK1 Q2M2I8 1/20 0.44
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA9 Q16790 2/20 0.43
POLB P06746 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
PTGS2 P35354 1/20 0.41
TSHR P16473 2/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
MAPK1 P28482 1/20 0.41
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
MCL1 Q07820 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28624037 0.86 SMN1; SMN2 (0.47) KDM4EIDO1AAK1CA12CA1
SCHEMBL5610352 0.85 IDO1 (0.45) KDM4EMAPTNPSR1IDO1CA12
SCHEMBL15151659 0.85 RAB9A (0.49) MAPTNPSR1TSHRMEN1KMT2A
SCHEMBL14804153 0.84 CA12 (0.46) KDM4EIDO1AAK1CA12CA1
SCHEMBL21601440 0.83 AAK1 (0.49) KDM4EMAPTIDO1AAK1CA12
SCHEMBL3453194 0.82 IDO1 (0.60) KDM4EMAPTIDO1CA12CA1
SCHEMBL10899699 0.82 CA12 (0.53) MAPTCA12CA1CA2CA9
SCHEMBL16593033 0.81 SUV39H2 (0.44) IDO1AAK1CA12CA1CA2
SCHEMBL17960659 0.81 CA12 (0.60) KDM4EMAPTNPSR1CA12CA1
SCHEMBL21601370 0.80 SCN9A (0.48) KDM4EIDO1AAK1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338429-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA, INC. (JP) 2012-12-25 US disclosed
US-20100222361-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222361-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF MPL, JAK2, ABL1 KDM4E 1499/4885MAPT 4550/4885NPSR1 3136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.